[{"id":"f7ed64ab-75a3-4068-9e72-e78962cb42af","acronym":"","url":"https://clinicaltrials.gov/study/NCT00487305","created_at":"2021-01-18T01:44:29.000Z","updated_at":"2024-07-02T16:35:30.113Z","phase":"Phase 1","brief_title":"Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma","source_id_and_acronym":"NCT00487305","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e allogeneic K562-GM tumor cell vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-11-07"},{"id":"99833e5b-3386-492c-8b0f-7ce88b4f5ffd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00301093","created_at":"2021-01-18T01:01:48.127Z","updated_at":"2024-07-02T16:36:39.509Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00301093","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • allogeneic K562-GM tumor cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 05/01/2007","primary_completion_date":" 05/01/2007","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2020-10-28"},{"id":"71d03369-b91d-4443-8790-1f498580a335","acronym":"","url":"https://clinicaltrials.gov/study/NCT00809250","created_at":"2021-01-18T03:04:29.271Z","updated_at":"2024-07-02T16:36:40.986Z","phase":"Phase 1","brief_title":"Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation","source_id_and_acronym":"NCT00809250","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e allogeneic K562-GM tumor cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/01/2008","start_date":" 11/01/2008","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-09-16"},{"id":"8ebfdba0-dd88-4626-a45a-0eeafc4134af","acronym":"","url":"https://clinicaltrials.gov/study/NCT00363649","created_at":"2021-01-18T01:15:40.038Z","updated_at":"2024-07-02T16:37:05.402Z","phase":"Phase 2","brief_title":"Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI","source_id_and_acronym":"NCT00363649","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Leukine (sargramostim) • allogeneic K562-GM tumor cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2018-11-13"},{"id":"db296820-93c4-4e26-9713-53261e7fdd7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00694330","created_at":"2021-01-18T02:35:41.361Z","updated_at":"2024-07-02T16:37:20.743Z","phase":"Phase 1","brief_title":"Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor","source_id_and_acronym":"NCT00694330","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e allogeneic K562-GM tumor cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 08/01/2009","primary_completion_date":" 08/01/2009","study_txt":" Completion: 08/01/2009","study_completion_date":" 08/01/2009","last_update_posted":"2017-06-22"}]